Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 19, 2003. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to corporate governance disclosures regarding share ownership.
Material Changes
The primary material change reported is a transaction involving the GlaxoSmithKline Employee Trust ("the GSK Trust"). On June 17, 2003, Abacus (GSK) Trustees Limited transferred 26,568 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The company was advised of these transactions on June 19, 2003.
Management Commentary and Risks
The filing notes that the GSK Trust is a discretionary trust where all employees or former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. Consequently, directors Dr. J-P Garnier and Mr. J D Coombe hold an interest in the shares held within the GSK Trust in the same capacity as other employees. No specific risks, contingencies, or unusual financial items are detailed in this text.
Investor Verification Checklist
- Verify the total number of shares transferred (26,568) and the specific plan involved (SmithKline Beecham Employee Share Option Plan 1991).
- Confirm the current beneficial ownership status of directors Dr. J-P Garnier and Mr. J D Coombe regarding the GSK Trust.
- Review the full terms of the GSK Trust to understand the scope of employee and director interests.